Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vasc...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Miller JD, Ye X, Lenhart GM, Farr AM, Tran OV, Kwong WJ, Magnuson EA, Weintraub WS
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Dove Medical Press 2016-05-01
Цуврал:	ClinicoEconomics and Outcomes Research
Нөхцлүүд:	edoxaban rivaroxaban cost-effectiveness non-valvular atrial fibrillation oral anticoagulation stroke
Онлайн хандалт:	https://www.dovepress.com/cost-effectiveness-of-edoxaban-versus-rivaroxaban-for-stroke-preventio-peer-reviewed-article-CEOR
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!